Precision Medicine for Hypertensive Disorders of Pregnancy—Are We There Yet?

Sadiya S. Khan,Sharlene M. Day
DOI: https://doi.org/10.1001/jamacardio.2023.5023
2024-03-14
JAMA Cardiology
Abstract:New-onset hypertensive disorders of pregnancy (HDPs) are a heterogeneous syndrome of interrelated vascular conditions. HDPs include gestational hypertension, preeclampsia, and eclampsia and are defined by elevated blood pressure (BP) beginning after 20 weeks' gestation with or without end-organ damage. HDPs affect nearly 1 in 6 pregnancies, represent an important risk factor for short- and long-term risk of cardiovascular disease (CVD), and share antecedent determinants with CVD. However, disease-modifying therapies for HDPs do not currently exist, and contemporary management approaches for HDPs focus primarily on targeting BP. Although a precision medicine approach to HDPs has garnered much enthusiasm, a better understanding of the underlying pathophysiology is first needed, which was recently highlighted by the Society for Maternal-Fetal Medicine and the Preeclampsia Foundation.
cardiac & cardiovascular systems
What problem does this paper attempt to address?